Semaglutide and early-stage metabolic abnormalities in individuals with schizophrenia spectrum disorders

JAMA Psychiatry

2025-12-03

(Press-News.org) About The Study: The results of this randomized clinical trial show that adjunctive semaglutide significantly improved glycemic control and weight outcomes in individuals with schizophrenia spectrum disorders. Secondary outcomes were exploratory. These findings support the use of glucagon-like peptide–1 receptor agonists (GLP-1RAs) as a potential early intervention strategy to reduce cardiometabolic risk in this vulnerable population.

Corresponding Author: To contact the corresponding author, Anders Fink-Jensen, DMSci, email anders.fink-jensen@regionh.dk.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(10.1001/jamapsychiatry.2025.3639)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2025.3639?guestAccessKey=a653e030-9988-447d-8e8d-57e394bab5bf&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=120325

END

ELSE PRESS RELEASES FROM THIS DATE:

Robert Wood Johnson University Hospital and Rutgers Robert Wood Johnson Medical School receive National Rare Disease Center of Excellence recognition

2025-12-03

Robert Wood Johnson University Hospital (RWJUH), an RWJBarnabas Health facility, in partnership with Rutgers Robert Wood Johnson Medical School (RWJMS), has been designated a National Rare Disease Center of Excellence by the National Organization for Rare Disorders (NORD). RWJUH is the first hospital in the state to receive this designation making New Jersey one of just 26 states in the U.S. to host such a Center of Excellence. RWJUH and RWJMS were selected for this designation based on the strength and impact of their Cardiac Amyloidosis Center, which was recently named an International Center of Excellence by the International Society of Amyloidosis (ISA). ...

The Mohn Prize for 2026 awarded to Canadian John Smol

2025-12-03

Professor John Smol of Queen's University is being honoured for his role in identifying stressors of environmental change in the Arctic. During the Arctic Futures Symposium in Brussels, UiT Rector Dag Rune Olsen announced today that the Mohn Prize for 2026 will be awarded to Professor John P. Smol of Queen’s University in Ontario, Canada. “Professor Smol's scientific career is a testament to excellent Arctic research - collaborative, engaged, thorough and key to the preservation of the environment we depend on. I am truly impressed by his comprehensive body of work and his longevity. He is a role model for us all.” said Olsen, who also ...

Americans more likely to accept guidance from AMA than CDC on vaccine safety

2025-12-03

PHILADELPHIA – For decades, health-related statements by major professional health associations such as the American Medical Association (AMA) agreed with those of the Centers for Disease Control and Prevention (CDC) because both relied on the same body of scientific knowledge, much of it funded by the federal health sector. However, the public can no longer assume that the CDC and major public health organizations are on the same page. In late November 2025, for example, when the CDC website legitimized the ...

How two Russian scientists changed the way we understand aging and cancer

2025-12-03

“Here, conceptual similarities between Mikhail Blagosklonny’s hyperfunction theory of aging and Vladimir Dilman’s elevation theory of aging are considered.” BUFFALO, NY — December 3, 2025 — A new essay was published in Volume 17, Issue 11 of Aging-US on November 19, 2025, titled “On the intergenerational transfer of ideas in aging and cancer research: from the hypothalamus according to V.M. Dilman to the mTOR protein complex according to M.V. Blagosklonny.” In this work, ...

Noninvasive imaging could replace finger pricks for people with diabetes

2025-12-03

CAMBRIDGE, MA -- A noninvasive method for measuring blood glucose levels, developed at MIT, could save diabetes patients from having to prick their fingers several times a day. The MIT team used Raman spectroscopy — a technique that reveals the chemical composition of tissues by shining near-infrared or visible light on them — to develop a shoebox-sized device that can measure blood glucose levels without any needles. In tests in a healthy volunteer, the researchers found that the measurements from their device were similar to those obtained by commercial ...

Genome Research publishes a special issue on advances in computational biology and their applications in genomics

2025-12-03

December 1, 2025 – This month Genome Research (https://genome.org) publishes a special issue highlighting novel advances in computational biology. In collaboration with the 29th International Conference on Research in Computational Molecular Biology (RECOMB), Genome Research publishes a collection of novel computational methods and their applications in genomics, including single-cell and spatial transcriptomics. These include algorithmic innovations in haplotype assembly and phasing, the analysis of genomic variation and its association to phenotype, and metagenomic ...

Announcing the 2025 Glenn Foundation for Medical Research Discovery Awards: Christina Camell, PhD (University of Minnesota) and Elaine Fuchs, PhD (The Rockefeller University)

2025-12-03

Santa Barbara, CA and New York, NY -- The Glenn Foundation for Medical Research (GFMR) and the American Federation for Aging Research (AFAR) are pleased to announce the 2025 recipients of the Glenn Foundation for Medical Research Discovery Awards: Christina Camell, PhD (Associate Professor, University of Minnesota) and Elaine Fuchs, PhD (Rebecca C. Lancefield Professor, The Rockefeller University and Investigator, Howard Hughes Medical Institute). The Glenn Foundation for Medical Discovery Awards support ...

Groundbreaking simulations show how black holes glow bright

2025-12-03

Surprisingly, some of the universe’s brightest objects are black holes. As scorching gas and dust flow around and into a black hole, they glow with fierce intensity across the light spectrum. Now, a team of computational astrophysicists has developed the most comprehensive simulations ever made of how black holes create these dazzling light shows. Using supercomputers, the researchers calculated the behavior of material zipping around black holes. Unlike all previous studies that relied on simplifying approximations, the researchers utilized a full treatment of how light moves and interacts with matter ...

When schizophrenia meets a personality disorder: why more research is urgently needed

2025-12-03

A new study by a research team at Université de Montréal highlights a critical lack of knowledge about the cognitive profiles of people living with both schizophrenia and a personality disorder. A comprehensive review of scientific literature from the past 24 years, published in Schizophrenia Research: Cognition, reveals that despite the high prevalence of this dual diagnosis (affecting approximately 40 per cent of people diagnosed with schizophrenia) and its association with unfavourable outcomes, the available data are surprisingly limited and fragmented. “Our analysis shows a significant blind spot in current ...

SwRI may have solved a mystery surrounding Uranus’ radiation belts

2025-12-03

SAN ANTONIO — December 3, 2025 — Southwest Research Institute (SwRI) scientists believe they may have resolved a 39-year-old mystery about the radiation belts around Uranus. In 1986, when Voyager 2 made the first and only flyby of Uranus, it measured a surprisingly strong electron radiation belt at significantly higher levels than anticipated. Based on extrapolations from other planetary systems, Uranus’ electron radiation belt was off the charts. Since then, scientists have wondered ...

Semaglutide and early-stage metabolic abnormalities in individuals with schizophrenia spectrum disorders

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: